Fibronectin as a Prognostic Indicator in Portal Hypertension
Author Information
Author(s): Ruth F. McKee, D.P. Maharaj, O.J. Garden, D.C. Carter
Primary Institution: University Department of Surgery and Department of Haematology, Royal Infirmary, Glasgow, UK
Hypothesis
The study aims to assess plasma fibronectin levels in patients with portal hypertension and their relation to liver disease severity and prognosis.
Conclusion
Plasma fibronectin levels are lower in patients who have had a recent variceal bleed, but alone are not an accurate predictor of one-year survival.
Supporting Evidence
- Mean plasma fibronectin level was 304.1 mg/ml.
- Lower fibronectin levels were found in patients who had a variceal bleed within the previous seven days.
- Only one of seven patients with low fibronectin and poor prognostic index survived for one year.
Takeaway
Doctors looked at a protein called fibronectin in patients with liver problems to see if it could help predict how long they would live, but it wasn't very reliable on its own.
Methodology
Plasma fibronectin levels were measured in patients with portal hypertension, and outcomes were recorded one year after blood sampling.
Limitations
The study included a heterogeneous group of patients, which may affect the accuracy of predicting prognosis.
Participant Demographics
Patients with portal hypertension and a history of bleeding oesophageal varices.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website